Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Reexamination Certificate
2005-07-26
2005-07-26
McKenzie, Thomas C. (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
Reexamination Certificate
active
06921825
ABSTRACT:
The compounds of the following formula:wherein R, R2, R3and A have the meanings given in the specification, are endowed with selective A3adenosine receptor antagonist activity. These compounds can be used in a pharmaceutical composition to treat disorders caused by excessive activation of the A3receptor, or can be used in a diagnostic application to determine the relative binding of other compounds to the A3receptor. The compounds can be labeled, for example with fluorescent or radiolabels, and the labels used in vivo or in vitro to determine the presence of tumor cells which possess a high concentration of adenosine A3receptors.
REFERENCES:
patent: 3625214 (1971-12-01), Higuchi
patent: 4789734 (1988-12-01), Pierschbacher
patent: 4906474 (1990-03-01), Langer et al.
patent: 4925673 (1990-05-01), Steiner et al.
patent: 5688774 (1997-11-01), Jacobson et al.
patent: 5780481 (1998-07-01), Jacobson et al.
patent: 6066642 (2000-05-01), Jacobson et al.
patent: 6117878 (2000-09-01), Linden
patent: 6326390 (2001-12-01), Leung et al.
patent: 6407236 (2002-06-01), Baraldi et al.
patent: 6448253 (2002-09-01), Baraldi et al.
patent: WO 95/01356 (1995-01-01), None
patent: WO 96/38728 (1996-12-01), None
patent: WO 97/05138 (1997-02-01), None
patent: WO 00/15231 (2000-03-01), None
Fishman, P. et al, Anticancer Drugs, 2002, 13(5), 437-43, Medline abstract PMID 12045454.
Muller, C.E. and Stein, B., Current Pharmaceutical Design, 1996, 2, 501-530.
Muller, C.E., Curr. Top. Med. Chem., 2003, 3(4), 445-462, Medline abstract PMID.
Fishman, P. et al, Curr. Top. Med. Chem., 2003, 3(4), 463-9, Medline abstract PMID 12570762.
B. Adcock, et al., “2-Amino-2-Imidazolines and 2-Amino-2-Oxalines,” J. Chem. Soc. 1961 pp. 5120-5127.
M. Abbracchio, et al., “G-Protein-Dependent Activation of Phospholipase C by Adenosine A3 Receptors in Rat Brain,” Mol. Pharmacol,. Dec., 1995; vol. 48, No. 6, pp. 1038-1045.
H. Ali, et al., “Sustained Activation of Phospholipase D via Adenosine A3 Receptors is Associated with Enhancement of Antigen-and Ca2+-Ionophore-Induced Secretion in a Rat Mast Cell Line,” J. Pharmacol. Exp. Ther., Feb., 1996, vol. 276, No. 2, pp. 837-845.
P. Baraldi, et al., “Synthesis of the Tritium Labeled SCH 58261, A New Non-Xanthine A2A Adenosine Receptor Antagonist,” J. of Labeled Com. & Radiopharm. 1996, vol. 37, No. 8, pp. 725-732.
P. Baraldi, et al., “Synthesis of 1H-Pyrazolo[4,3-D]Pyrimidine-7(6H)-Ones and Pyrazolo-5-Carboxamides and Interaction with Benzodiazepine and Adenosine A1 Receptors in Rat Cerebral Cortex,” Arzneim. Forsch. Drug Res., 1988, vol. 38, No. 11, pp. 1262-1265.
P. Baraldi, et al., “Synthesis and Biological Activity of a New Series of N6-Arylcarbamoyl, 2-(AR)Alkynyl-N6-Arylcarbamoyl, and N6-Carboxamido Derivatives of Adenosine-5′-N-Ethyluronamide as A1 and A3 Adenosine Receptor Agonists,” J. Med. Chem. Aug. 13, 1998, vol. 41, No. 17, pp. 3174-3185.
P. Baraldi, et al., “Synthesis of New Pyrazolo[4,3-e] 1,2,4-Triazolo [1,5-c] Pyrimidine Displaying Potent and Selective Activity as A2A Adenosine Receptor Antagonists,” Bioorg. Med. Chem. Lett. 1994, vol. 4, No. 21, pp. 2539-2544.
P. Baraldi, et al., “Novel N6-(Substituted-Phenylcarbamoyl) Adenosine-5′-Uronamides as Potent Agonists for A3 Adenosine Receptors,” J. Med. Chem., Feb. 2, 1996, vol. 39, No. 3, pp. 802-806.
P. Baraldi, et al., “Pyrazolo[4,3-e]-1,2,4-Triazolo[1,5-c]Pyrimidine Derivatives: Potent and Selective A2A Adenosine Antagonists,” J. Med. Chem., Mar. 1, 1996 vol. 39, No. 5, pp. 1164-1171.
P. Baraldi, et al., “Design Synthesis, and Biological Evaluation of a Second Generation of Pyrazolo[4,3-e]-1,2,4-Triazolo[1,5-c] Pyrimidines as Potent and Selective A2A Adenosine Receptor Antagonists,” J. Med. Chem., Jun. 4, 1998, vol. 41, NO 12, pp. 2126-2133.
P. Baraldi, et al., “Current Developments of A2A Adenosine Receptor Antagonists,” Curr. Med. Chem., 1995, vol. 2, pp. 707-722.
P. Barladi, et al., “1,2,3-Triazolo[5,4-e]1,2,4-Triazolo[1,5-c] Pyrimidine Deritivies: A New Class of A2A Adenosine Receptor Antagonists,” IL Farmaco, 1996, vol. 51, No. 4, pp. 297-300.
P. Baraldi, et al., “1H-Pyrazolo[4,3-d] Pyrimidine-7(6H)-One and 5H-Pyrazolo[4,3-d] 1,2,3-Triazin-4(3H)-One Derivatives and Synthesis and In Vitro Biological Activity at Adenosine A1 and A2A Receptors,” Arzneimittelforschung. Apr. 1996, vol. 46, No. 4, pp. 365-368.
P. Baraldi, et al., “Synthesis of 3-Substituted-7-Alkoxy-5H-Pyrazolo[4,3-d]-1,2,3-Triazin-4-(3H)-Ones,” Dec. 1994, vol. 12, pp. 1437-1440.
P. Baraldi, et al., “Synthesis and Preliminary Biological Evaluation of [3H]-MRE 3008-F20: The First High Affinity Radioligand Antagonist for the Human A3 Adenosine Receptors,” Bioorg. & Med. Chem. Letters, 2000, vol. 10, pp. 209-211.
M. Bradford, “A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding,” Anal. Biochem., May 7, 1976, vol. 72, pp. 248-254.
R. Bruns, et al., “Adenosine Receptors in Brain Membranes: Binding of N6-Cyclohexyl [3H] Adenosine and 1,3-Diethyl-8-[3H] Phenylxanthine,” Proc., Natl. Acad. Sci. USA, Sep. 1980, vol. 77, No. 9, pp. 5547-5551.
Y. Cheng, et al., “Relationship Between the Inhibition Constant (KI) and the Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (I50) of an Enzymatic Reaction,” Biochem. Pharm., Dec. 1, 1973, vol. 22, No. 23, pp. 3099-3108.
C. Cheng, et al., Potential Purine Antagonists. VI. Synthesis of 1-Alkyl-and 1-Aryl-4-Substituted Pyrazolo[3,4-d] Pyrimidines, J. Org. Chem., 1956, vol. 21, pp. 1240-1258.
L. Colombetti, “Principles of Radiopharmacology,” CRC Press, 1979, pp. 11-13, and 24.
P. Crooks, et al., “Synthesis of 5-Benzoyl-5-Phenyl-and 5-Phenylhydroxymethyl-5-Phenylhydantoins as Potential Anticonvulsants,” J. Heter. Chem., Jul.-Aug. 1989, vol. 26, No. 4, pp. 1113-1117.
M. DeNinno, et al., Annual Reports in Medicinal Chemistry, 33, 1998, pp. 111-120.
B. Fredholm, et al., “Nomenclature and Classification of Purinoceptors,” Pharm. Rev., Jun. 1994, vol. 46, No. 2, pp. 143-156.
G. Gregoriades, “Liposomes,” Drug Carriers in Biology and Med., 1979, pp. 287-341.
J. Hannon, et al., “A Role for Mast Cells in Adenosine A3 Receptor-Mediated Hypotension in the Rat,” British Journal of Pharm., Jul. 1995, vol. 115, No. 6, pp. 945-952.
R. Hill, et al., “Cloning, Expression and Pharmacological Characterization of Rabbit Adenosine A1 and A3 Receptors,” J. Pharmacol. Exp. Ther., Jan. 1997, vol. 280, No. 1, pp. 122-128.
A. Howlett, “Pharmacology of Cannabinoid Receptors,” Ann. Rev. Pharmacol. Toxicol. 1995, vol. 35, pp. 607.
K. Jacobson, “Adenosine A3 Receptors: Novel Ligands and Paradoxical Effects,” Trends Pharmacol. Sci., May 1998, vol. 19, No. 5, pp. 184-191.
K. Jacobson, et al., “Recent Developments in Selective Agonists and Antagonists Acting at Purine and Pyrimidine Receptors,” Drug Dev. Res. 1996, vol. 39, pp. 4667-4675.
K. Jacobson, et al., “Development of Selective Purinoceptor Agonists and Antagonists” Purinergic Approaches in Experimental Therapeutics, 1997, vol. 6, pp. 101-128.
J. Jiang, et al., “6-Phenyl-1,4-Dihydropyridine Derivatives as Potent and Selective A3 Adenosine Receptor Antagonists,” J. Med. Chem. Nov. 8, 1996, vol. 39, No. 23, pp. 4667-4675.
J. Jiang, et al., “Structure-Activity Relationships of 4-(Phenylethynyl)-6-Phenyl-1,4-dihydropyridines as Highly Selective A3 Adenosine Receptor Antagonists,” J. Med. Chem., Aug. 1, 1997, vol. 40, No. 16, pp. 2596-2608.
J. Kagan, et al., “The Synthesis and Photochemistry of 4-Amino-3-Cyanopyrazole,” J. Heter. Chem., Sep. 1979, vol. 16, No. 6, pp. 1113-1115.
Y. Karton, et al., “Synthesis and Biological Activities of Flavornoid Derivatives
Baraldi Pier Giovanni
Borea Pier Andrea
Butler, Esq. Gregory B.
Conlin, Esq. David G.
King Pharmaceuticuals Research & Development, Inc.
McKenzie Thomas C.
LandOfFree
Adenosine A3 receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adenosine A3 receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adenosine A3 receptor modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3377062